Hagay Hagay, Asaf Achiron, Dua Maswuara, Mordechai Goldberg
{"title":"[ROCK (RHO-KINASE INHIBITORS) FOR THE TREATMENT OF OPEN-ANGLE GLAUCOMA AND OCULAR HYPERTENSION].","authors":"Hagay Hagay, Asaf Achiron, Dua Maswuara, Mordechai Goldberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Netarsudil ophthalmic solution 0.02% is a new treatment for open-angle glaucoma and ocular hypertension, which was approved for treatment in the United States and in the European Commission. The drug is a rho- kinase inhibitor (ROCK) that lowers intraocular pressure by enhancing the outflow at the trabecular meshwork and decreasing both aqueous humor production and episcleral venous pressure. This literature review aims to present this new treatment, characterize its specific mechanism of action, and discuss its effect and adverse events profile. The efficacy and safety of the drug were studied in the ROCKET and MERCURY clinical trials, in which Netarsudil was compared to other common drugs, including Timolol (Beta-blocker), Latanoprost (Prostaglandin analog), and a combination drop containing Netarsudil and Latanoprost. These trials showed a reduction of 16%-21% in the intraocular pressure (IOP) when using Netarsudil. Moreover, it was found that when using a combination of Netarsudil and Latanoprost, 64.5% of these patients achieved ≥30% reduction in mean diurnal IOP versus 28.8% of patients treated only with Netarsudil and 37.2% of patients treated only with Latanoprost (P<0.0001). The most common adverse event reported was conjunctival hyperemia, which was more frequent in patients using Netarsudil. However, this did not significantly affect the drug tolerance.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 3","pages":"160-164"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9244373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Racheli Mezan, Inbal Amit, Erez Barenboim, Sarah Cohen
{"title":"[IMPLEMENTATION OF AN INNOVATIVE PROGRAM - PROFESSIONAL NURSING COMPETENCE ADAPTED TO CLINICAL NEEDS TO IMPROVE THE PROFESSIONAL QUALITY AND QUALITY OF CARE AT ASSUTA ASHDOD PUBLIC HOSPITAL].","authors":"Racheli Mezan, Inbal Amit, Erez Barenboim, Sarah Cohen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Health systems in Israel and around the world are facing an increase in life expectancy and chronic diseases, along with technological developments, healthcare transparency, and increased customer (patients') requirements. Medical teams must provide high professional responses to these challenges. Nurse training in Israel occurs on both academic and professional levels. The last decade has shown an academic trend in the nursing profession, where most training options integrate a bachelor's degree and a registered nurse certificate. At the professional level, academic nurses can expand their professional competence through advanced clinical training, and a nurse practitioner program. There is a growing trend among policy makers for placing nurses with such recognized training in various key positions such as head nurse, and shift managers in specific wards and units.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 3","pages":"165-170"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9244374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[PHYSICAL ACTIVITY DURING PREGNANCY AND AFTER BIRTH].","authors":"Amit Elbaz Braun, Ido Solt, Naama Constantini","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Physical activity (PA) decreases morbidity, improves quality of life and elongates life span. PA during pregnancy is safe and decreases complications. Physical inactivity during pregnancy is an independent risk factor for maternal weight gain and complications. Pregnancy is a golden opportunity to promote a healthy lifestyle.</p><p><strong>Objectives: </strong>This article aims to review the latest recommendations regarding PA in pregnancy. In this article we focused on the following: The joint guidelines of the Society of Obstetricians and Gynaecologists of Canada's (SOGC) and the Canadian Society for Exercise Physiology (CSEP), the American College of Obstetricians and Gynecologists (ACOG) committee opinion, and the ACSM's (American College of Sports Medicine) Guidelines for Exercise Testing and Prescription, the 11th Edition published in 2019, 2020 and 2022 respectively.</p><p><strong>Conclusions: </strong>PA during pregnancy is safe and essential. Every pregnant woman without contraindications should perform 150 weekly minutes of aerobic exercise and resistance training.</p><p><strong>Discussion: </strong>A weekly goal of 150 medium intensity aerobic exercise minutes spread over at least 3 separate days combined with resistance training is recommended for every pregnant woman, including women who were inactive prior to the pregnancy, those diagnosed with gestational diabetes and overweight or obese women. Pregnant women with absolute contraindication can continue to perform their daily activities but avoid more intense activities, those with relative contraindications should discuss the advantages and risks of PA with their attending physician. After birth, women can return to PA gradually depending on the mode of delivery and complications encountered.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 3","pages":"146-151"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9244378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[POST-ARTEMISININ DELAYED HEMOLYSIS AFTER TREATMENT OF MALARIA].","authors":"Nadav Baharav, Eli Schwartz","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Falciparum malaria is highly endemic in sub-Saharan Africa. The disease is caused by the intra-cellular parasite Plasmodium within erythrocytes. The recommended treatment is artemisinin-based combination which is efficient and safe. In some patients, artemisinin can cause hemolysis weeks after treatment, presenting with severe anemia. Most of the published cases were following intravenous treatment. We present a case of a falciparum malaria patient with hemolysis and severe anemia two weeks after oral treatment with artemisinin-based combination therapy.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 3","pages":"143-145"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9559522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[[PTOSIS AS A SIGN OF A SYSTEMIC DISEASE]].","authors":"Roee Arnon, Avi Rubinov","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 2","pages":"119-121"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9548907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[TREATMENT OF SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSRIS AND SNRIS) DURING PREGNANCY AND LACTATION].","authors":"Lihi Rozner, Gabi Aisenberg Romano, Chagit Klieger, Miki Bloch","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Women are more likely to develop depression during the perinatal period than at any other time in their lives. Studies from recent years raise significant concerns regarding the potential of a depressive disorder in the pregnant mother to cause adverse obstetric results for the mother and the newborn. As antidepressants can penetrate the placenta to different degrees, concern has been raised regarding their teratogenic potential. In recent years various inconsistent and ambiguous reports specifying mild risks to the fetus and newborn from exposure to serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) during pregnancy have been published. This paper provides a review of current medical knowledge regarding the pharmacological treatment with common antidepressants such as SSRIs and SNRIs in pregnant women. Based on this review we also present treatment and follow-up recommendations of the major published guidelines for the treatment of serotonin and norepinephrine reuptake inhibitors (SSRIs and SNRIs) during pregnancy for the medical care providers.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 2","pages":"86-91"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9119044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[LASER INTERSTITIAL THERMAL THERAPY (LITT) IN NEUROSURGERY].","authors":"Rachel Grossman, Ido Strauss","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Laser interstitial thermal therapy (LITT) has emerged as a new treatment option for various conditions within the neurosurgery world, not only due to its minimal invasiveness but also because it has been shown to be safe and effective. Combined with magnetic resonance thermography, LITT gives surgeons the ability to estimate damage in real time and precisely ablate the target tissue while minimizing thermal damage to adjacent structures. In recent years, LITT has become a reality in epilepsy surgery and in neuro-oncology and is emerging as an option in other fields in neurosurgery.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 2","pages":"110-115"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9113216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Noa Schwartz, Ramiz Abu Shkara, Felix Benninger, Sagi Harnof, Idit Tamir
{"title":"[CHANGING CONCEPTS IN THE CLINICAL APPROACH FOR EPILEPSY SURGERY].","authors":"Noa Schwartz, Ramiz Abu Shkara, Felix Benninger, Sagi Harnof, Idit Tamir","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Epilepsy is a common disease state, occurring in approximately 1% of the population worldwide, including both pediatric and adult populations. It is characterized by recurrent episodes of unpredictable pathologic cortical brain activity. One-third of patients develop drug intractability and experience recurrent seizures, despite optimal treatment. These result in cognitive decline, behavioral changes, decreased quality of life, and increased risk for trauma and death (SUDEP- sudden unprovoked death from epilepsy). Therefore, the international league against epilepsy (ILAE) recommends referral of intractable patients to highly specialized epilepsy centers, for further evaluation for epilepsy surgery.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 2","pages":"103-109"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9119050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[DEEP ORBITAL DERMOID CYSTS].","authors":"Lee Nusbaum, Michael Paul, Idit Maharshak","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Orbital dermoid cysts are benign choristomas that arise from the entrapment of ectodermal elements adjacent to the fetal bony suture lines. They are considered congenital, but not all are diagnosed at birth. They are the most common orbital tumors in children. While superficial dermoid cysts appear early in life, deep dermoid cysts remain clinically occult until adolescence or adulthood, when they enlarge and may cause proptosis, ocular and orbital symptoms, and even neurological symptoms. In addition, many deep orbital dermoid cysts present with chronic inflammation resulting from lipid leakage from the cysts. They pose a diagnostic and therapeutic challenge, require radiological imaging for planning the surgical approach and may be difficult to remove. Early diagnosis and complete surgical removal of the cysts are the recommended therapeutic approach. In this paper, we present a literature review of deep orbital dermoid cysts to provide useful guidance for their diagnosis and management.</p>","PeriodicalId":12965,"journal":{"name":"Harefuah","volume":"162 2","pages":"98-102"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9113218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}